NASDAQ:ARIA - Ariad Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $23.99 +23.99 (+∞) (As of 02/17/2017)Previous Close$23.99Today's Range$23.99 - $23.9952-Week Range$4.67 - $23.99VolumeN/AAverage Volume15.70 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR). Receive ARIA News and Ratings via Email Sign-up to receive the latest news and ratings for ARIA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryBiotechnology SectorN/A Current SymbolNASDAQ:ARIA Previous Symbol CUSIP04033A10 CIK884731 Webwww.ariad.com Phone+1-617-4940400Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableOptionable Ariad Pharmaceuticals (NASDAQ:ARIA) Frequently Asked Questions What is Ariad Pharmaceuticals' stock symbol? Ariad Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARIA." How were Ariad Pharmaceuticals' earnings last quarter? Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) released its quarterly earnings data on Thursday, July, 28th. The pharmaceutical company reported $0.59 earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.70. The pharmaceutical company earned $65.30 million during the quarter, compared to analyst estimates of $60.64 million. The business's quarterly revenue was up 133.0% compared to the same quarter last year. During the same period last year, the business earned ($0.28) earnings per share. View Ariad Pharmaceuticals' Earnings History. Has Ariad Pharmaceuticals been receiving favorable news coverage? Media coverage about ARIA stock has been trending positive this week, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ariad Pharmaceuticals earned a news sentiment score of 2.1 on InfoTrie's scale. They also assigned media headlines about the pharmaceutical company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the near term. What other stocks do shareholders of Ariad Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ariad Pharmaceuticals investors own include Twitter (TWTR), Synergy Pharmaceuticals (SGYP), Gilead Sciences (GILD), Exelixis (EXEL), ACADIA Pharmaceuticals (ACAD), Tesla (TSLA), Netflix (NFLX), Bank of America (BAC), Alphabet (GOOG) and Novavax (NVAX). How do I buy shares of Ariad Pharmaceuticals? Shares of ARIA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Ariad Pharmaceuticals' stock price today? One share of ARIA stock can currently be purchased for approximately $23.99. What is Ariad Pharmaceuticals' official website? The official website for Ariad Pharmaceuticals is http://www.ariad.com. How can I contact Ariad Pharmaceuticals? Ariad Pharmaceuticals' mailing address is 125 Binney St, CAMBRIDGE, MA 02142-1123, United States. The pharmaceutical company can be reached via phone at +1-617-4940400. MarketBeat Community Rating for Ariad Pharmaceuticals (NASDAQ ARIA)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 523 (Vote Outperform)Underperform Votes: 401 (Vote Underperform)Total Votes: 924MarketBeat's community ratings are surveys of what our community members think about Ariad Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARIA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARIA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/24/2019 by MarketBeat.com StaffFeatured Article: Dividend Stocks - Are They Right For You?